Case number 2019-1147
BTG International Limited v. Amneal Pharmaceuticals LLC > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Apr 23, 2021 | 0 | BTG INTERNATIONAL LIMITED v. AMNEAL PHARMACEUTICALS LLC [OPINION - PRECEDENTIAL] [precedential] (0) |
| Jun 20, 2019 | 159 | Mandate issued to the United States District Court for the District of New Jersey (19-1147, 19-1148) and United States Patent and Trademark Office (19-1323, 19-1324, 19-1325). Service as of this date by the Clerk of Court. [615845] [19-1147, 19-1148, 19-1323, 19-1324, 19-1325] [MJL] [Entered: 06/20/2019 02:59 PM] (4) |
| May 14, 2019 | 157 | OPINION filed for the court by Moore, Circuit Judge; Wallach, Circuit Judge and Chen, Circuit Judge. Precedential Opinion. [607100] [19-1147, 19-1148, 19-1323, 19-1324, 19-1325] [JAB] [Entered: 05/14/2019 10:13 AM] (27) |
| May 14, 2019 | 158 | JUDGMENT filed. DISMISSED in Nos. 2019-1147, 2019-1148, 2019-1323, 2019-1324; AFFIRMED in No. 2019-1325. Terminated on the merits after oral argument. COSTS: Costs taxed against Appellant(s). Mandate to issue in due course. For information regarding costs, petitions for rehearing, and petitions for writs of certiorari click here. [607102] [JAB] [Entered: 05/14/2019 10:15 AM] (4) |
| Mar 14, 2019 | 156 | Submitted after ORAL ARGUMENT by Thomas W. Krause for Iancu, Constantine L. Trela, Jr. for BTG International Limited, Janssen Biotech, Inc., Janssen Oncology, Inc. and Janssen Research & Development, LLC and Nathan K. Kelley for Amerigen Pharmaceuticals Limited, Amerigen Pharmaceuticals, Inc., Amneal Pharmaceuticals LLC, Amneal Pharmaceuticals of New York, LLC, Argentum Pharmaceuticals LLC, Dr. Reddy's Laboratories, Inc., Dr. Reddy's Laboratories, Ltd., Hikma Pharmaceuticals LLC, Mylan Inc., Mylan Pharmaceuticals Inc., Teva Pharmaceuticals USA, Inc., West-Ward Pharmaceuticals Corp., Wockhardt Bio AG, Wockhardt Ltd. and Wockhardt USA LLC. Panel: Judge: Moore , Judge: Wallach , Judge: Chen. [592767]--[Edited 03/14/2019 by JAB to correct docket text] [JCP] [Entered: 03/14/2019 10:15 AM] (0) |
| Mar 7, 2019 | 155 | Joint Statement of Compliance with Fed. Cir. R. 33 for Appellants BTG International Limited, Janssen Biotech, Inc., Janssen Oncology, Inc., Janssen Research & Development, LLC and Appellees Wockhardt USA LLC, Wockhardt Ltd., Wockhardt Bio AG and Argentum Pharmaceuticals LLC. Service: 03/07/2019 by email. [591276] [19-1147] [Constantine Trela] [Entered: 03/07/2019 04:24 PM] (7) |
| Mar 6, 2019 | 144 | MODIFIED ENTRY: JOINT APPENDIX FILED for Appellants BTG International Limited, Janssen Biotech, Inc., Janssen Oncology, Inc., and Janssen Research & Development, LLC. Number of Pages: 2343. Service: 03/06/2019 by email. [590748] --[Edited 03/06/2019 by JAL - Compliance review complete] [Constantine Trela] [Entered: 03/06/2019 12:40 PM] (2343) |
| Mar 6, 2019 | 145 | MODIFIED ENTRY: CONFIDENTIAL JOINT APPENDIX FILED (Volumes I-IV) for Appellants BTG International Limited, Janssen Biotech, Inc., Janssen Oncology, Inc., and Janssen Research & Development, LLC. Number of Pages: 1894. Service: 03/06/2019 by email, US mail. [590752]--[Edited 03/06/2019 by JAL - Compliance review complete] [Constantine Trela] [Entered: 03/06/2019 12:44 PM] (0) |
| Mar 6, 2019 | 146 | MODIFIED ENTRY: CONFIDENTIAL JOINT APPENDIX FILED (Volumes V-VI) for Appellants BTG International Limited, Janssen Biotech, Inc., Janssen Oncology, Inc., and Janssen Research & Development, LLC. Number of Pages: 485. Service: 03/06/2019 by email, US mail. [590756]--[Edited 03/06/2019 by JAL - Compliance review complete] [Constantine Trela] [Entered: 03/06/2019 12:47 PM] (0) |
| Mar 6, 2019 | 147 | Outstanding paper copies of all briefs and appendices must be submitted by 03/08/2019. See Fed. Cir. R. 25(c)(1). [590831] [JAL] [Entered: 03/06/2019 02:47 PM] (0) |
| Mar 6, 2019 | 148 | Certificate of Compliance with Fed. Cir. R. 11(d) (Trial Court) for Appellees Amerigen Pharmaceuticals Limited, Amerigen Pharmaceuticals, Inc., Amneal Pharmaceuticals LLC, Amneal Pharmaceuticals of New York, LLC, Argentum Pharmaceuticals LLC, Dr. Reddy's Laboratories, Inc., Dr. Reddy's Laboratories, Ltd., Hikma Pharmaceuticals LLC, Mylan Inc., Mylan Pharmaceuticals Inc., Teva Pharmaceuticals USA, Inc., West-Ward Pharmaceuticals Corp., Wockhardt Bio AG, Wockhardt Ltd. and Wockhardt USA LLC. Service: 03/06/2019 by email. [590852] [19-1147] [Dan Bagatell] [Entered: 03/06/2019 03:09 PM] (6) |
| Mar 6, 2019 | 149 | Certificate of Compliance with Fed. Cir. R. 17 (Agency) for Appellees Amerigen Pharmaceuticals Limited, Amerigen Pharmaceuticals, Inc., Amneal Pharmaceuticals LLC, Amneal Pharmaceuticals of New York, LLC, Argentum Pharmaceuticals LLC, Dr. Reddy's Laboratories, Inc., Dr. Reddy's Laboratories, Ltd., Hikma Pharmaceuticals LLC, Mylan Inc., Mylan Pharmaceuticals Inc., Teva Pharmaceuticals USA, Inc., West-Ward Pharmaceuticals Corp., Wockhardt Bio AG, Wockhardt Ltd. and Wockhardt USA LLC. Service: 03/06/2019 by email. [590854] [19-1147] [Dan Bagatell] [Entered: 03/06/2019 03:10 PM] (6) |
| Mar 6, 2019 | 150 | Certificate of Compliance with Fed. Cir. R. 17 (Agency) for Appellants BTG International Limited, Janssen Biotech, Inc., Janssen Oncology, Inc. and Janssen Research & Development, LLC. Service: 03/06/2019 by email. [590869] [19-1147] [Constantine Trela] [Entered: 03/06/2019 03:24 PM] (6) |
| Mar 6, 2019 | 151 | Certificate of Compliance with Fed. Cir. R. 11(d) (Trial Court) for Appellants BTG International Limited, Janssen Biotech, Inc., Janssen Oncology, Inc. and Janssen Research & Development, LLC. Service: 03/06/2019 by email. [590873] [19-1147] [Constantine Trela] [Entered: 03/06/2019 03:26 PM] (6) |
| Mar 6, 2019 | 152 | 6 paper copies of the Confidential Joint Appendix Brief (Vol. I - IV) [145] received from Appellants BTG International Limited, Janssen Biotech, Inc., Janssen Oncology, Inc. and Janssen Research & Development, LLC. [590904]--[Edited 03/07/2019 by JCP] [CJF] [Entered: 03/06/2019 04:20 PM] (0) |
| Mar 6, 2019 | 153 | 6 paper copies of the Confidential Joint Appendix Brief (V - VI) [146] received from Appellants BTG International Limited, Janssen Biotech, Inc., Janssen Oncology, Inc. and Janssen Research & Development, LLC. [590919]--[Edited 03/07/2019 by JCP] [CJF] [Entered: 03/06/2019 04:42 PM] (0) |
| Mar 6, 2019 | 154 | Joint Statement of Compliance with Fed. Cir. R. 33 for Appellees Amerigen Pharmaceuticals Limited, Amerigen Pharmaceuticals, Inc., Amneal Pharmaceuticals LLC, Amneal Pharmaceuticals of New York, LLC, Dr. Reddy's Laboratories, Inc., Dr. Reddy's Laboratories, Ltd., Hikma Pharmaceuticals LLC, Mylan Inc., Mylan Pharmaceuticals Inc., Teva Pharmaceuticals USA, Inc., West-Ward Pharmaceuticals Corp. and Appellants BTG International Limited, Janssen Biotech, Inc., Janssen Oncology, Inc. and Janssen Research & Development, LLC. Service: 03/06/2019 by email. [590958] [19-1147] [Constantine Trela] [Entered: 03/06/2019 08:41 PM] (9) |
| Feb 28, 2019 | 142 | MODIFIED ENTRY: REPLY BRIEF FILED for Appellants BTG International Limited, Janssen Biotech, Inc., Janssen Oncology, Inc. and Janssen Research & Development, LLC. Number of Pages: 31. Service: 02/28/2019 by email. [589469] --[Edited 02/28/2019 by JAL - Compliance review complete] [Constantine Trela] [Entered: 02/28/2019 03:09 PM] (47) |
| Feb 28, 2019 | 143 | 6 paper copies of the Reply Brief [142] received from Appellants BTG International Limited, Janssen Biotech, Inc., Janssen Oncology, Inc. and Janssen Research & Development, LLC. [589483] [CJF] [Entered: 02/28/2019 03:36 PM] (0) |
| Feb 25, 2019 | 140 | 6 paper copies of the Amicus Brief [139] received from Amicus Curiae Association for Accessible Medicines. [588337] [CJF] [Entered: 02/25/2019 12:16 PM] (0) |
| Feb 25, 2019 | 141 | Certificate of Interest for the Amicus Curiae Association for Accessible Medicines. Service: 02/25/2019 by email. [588339] [19-1147] [William Jay] [Entered: 02/25/2019 12:25 PM] (3) |
| Feb 22, 2019 | 136 | Entry of appearance for Jeffrey Francer as of counsel for The Association for Accessible Medicines. Service: 02/22/2019 by email. [588131] [19-1147] [Jeffrey Francer] [Entered: 02/22/2019 04:37 PM] (2) |
| Feb 22, 2019 | 137 | Entry of appearance for Joshua J. Bone as of counsel for The Association for Accessible Medicines. Service: 02/22/2019 by email. [588138] [19-1147] [Joshua Bone] [Entered: 02/22/2019 04:41 PM] (2) |
| Feb 22, 2019 | 138 | Entry of appearance for William M. Jay as principal counsel for The Association for Accessible Medicines. Service: 02/22/2019 by email. [588141] [19-1147] [William Jay] [Entered: 02/22/2019 04:43 PM] (2) |
| Feb 22, 2019 | 139 | MODIFIED ENTRY: AMICUS CURIAE BRIEF FILED for Association for Accessible Medicines. Number of Pages: 30. Service: 02/22/2019 by email. (Clerk's Note: The Certificate of Interest should be submitted as a separate filing promptly.) [588147]--[Edited 02/25/2019 by JAL - Compliance review complete] [William Jay] [Entered: 02/22/2019 04:49 PM] (41) |
| Feb 21, 2019 | 135 | 6 paper copies of the Opening Response Brief [132] received from Appellees Amerigen Pharmaceuticals Limited, Amerigen Pharmaceuticals, Inc., Amneal Pharmaceuticals LLC, Amneal Pharmaceuticals of New York, LLC, Argentum Pharmaceuticals LLC, Dr. Reddy's Laboratories, Inc., Dr. Reddy's Laboratories, Ltd., Hikma Pharmaceuticals LLC, Mylan Inc., Mylan Pharmaceuticals Inc., Teva Pharmaceuticals USA, Inc., West-Ward Pharmaceuticals Corp., Wockhardt Bio AG, Wockhardt Ltd. and Wockhardt USA LLC. [587713] [CJF] [Entered: 02/21/2019 03:19 PM] (0) |
| Feb 19, 2019 | 132 | MODIFIED ENTRY: RESPONSE BRIEF FILED for Appellees Amerigen Pharmaceuticals Limited, Amerigen Pharmaceuticals, Inc., Amneal Pharmaceuticals LLC, Amneal Pharmaceuticals of New York, LLC, Argentum Pharmaceuticals LLC, Dr. Reddy's Laboratories, Inc., Dr. Reddy's Laboratories, Ltd., Hikma Pharmaceuticals LLC, Mylan Inc., Mylan Pharmaceuticals Inc., Teva Pharmaceuticals USA, Inc., West-Ward Pharmaceuticals Corp., Wockhardt Bio AG, Wockhardt Ltd. and Wockhardt USA LLC. Number of Pages: 65. Service: 02/15/2019 by email. [586751] --[Edited 02/19/2019 by JAL - Compliance review complete] [Dan Bagatell] [Entered: 02/16/2019 10:00 PM] (89) |
| Feb 19, 2019 | 133 | CLERK'S OFFICE QUALITY CONTROL MESSAGE: re:Opening Response Brief Docket No. [132], ERROR: The contact information listed on the cover of the brief for William Hare and Christopher Casieri does not match the information in the attorneys' user accounts or entries of appearance. CORRECTION: Please update as needed to ensure that the information on the user accounts, entries of appearance, and briefs matches. Please submit an amended entry of appearance if necessary. THIS MESSAGE IS FOR INFORMATIONAL PURPOSES ONLY. [586920] [JAL] [Entered: 02/19/2019 11:25 AM] (0) |
| Feb 19, 2019 | 134 | 6 paper copies of the Opening Response Brief [132] received from Appellees Amerigen Pharmaceuticals Limited, Amerigen Pharmaceuticals, Inc., Amneal Pharmaceuticals LLC, Amneal Pharmaceuticals of New York, LLC, Argentum Pharmaceuticals LLC, Dr. Reddy's Laboratories, Inc., Dr. Reddy's Laboratories, Ltd., Hikma Pharmaceuticals LLC, Mylan Inc., Mylan Pharmaceuticals Inc., Teva Pharmaceuticals USA, Inc., West-Ward Pharmaceuticals Corp., Wockhardt Bio AG, Wockhardt Ltd. and Wockhardt USA LLC. [586986] [CJF] [Entered: 02/19/2019 12:41 PM] (0) |
| Feb 15, 2019 | 131 | Response to notice of oral argument from the Appellees Amerigen Pharmaceuticals Limited, Amerigen Pharmaceuticals, Inc., Amneal Pharmaceuticals LLC, Amneal Pharmaceuticals of New York, LLC, Argentum Pharmaceuticals LLC, Dr. Reddy's Laboratories, Inc., Dr. Reddy's Laboratories, Ltd., Hikma Pharmaceuticals LLC, Mylan Inc., Mylan Pharmaceuticals Inc., Teva Pharmaceuticals USA, Inc., West-Ward Pharmaceuticals Corp., Wockhardt Bio AG, Wockhardt Ltd. and Wockhardt USA LLC. [586509] [19-1147] [Nathan Kelley] [Entered: 02/15/2019 03:31 PM] (3) |
| Feb 12, 2019 | 129 | Response to notice of oral argument from the Amicus Curiae Iancu. [585234] [19-1147] [Thomas Krause] [Entered: 02/12/2019 01:16 PM] (3) |
| Feb 12, 2019 | 130 | Entry of appearance for Nathan K. Kelley as of counsel for Appellees Mylan Inc. and Mylan Pharmaceuticals Inc.. Service: 02/12/2019 by email. [585253] [19-1147] [Nathan Kelley] [Entered: 02/12/2019 01:52 PM] (2) |
| Feb 11, 2019 | 128 | 6 paper copies of the Corrected Confidential Opening Brief [116] received from Appellants BTG International Limited, Janssen Biotech, Inc., Janssen Oncology, Inc. and Janssen Research & Development, LLC. [584784] [CJF] [Entered: 02/11/2019 12:20 PM] (0) |
| Feb 8, 2019 | 125 | 6 paper copies of the Corrected Confidential Opening Brief [116] received from Appellants BTG International Limited, Janssen Biotech, Inc., Janssen Oncology, Inc. and Janssen Research & Development, LLC. [584540] These documents are non-compliant. See Doc No.[127] [CJF] [Entered: 02/08/2019 02:43 PM] (0) |
| Feb 8, 2019 | 126 | 6 paper copies of the Amicus Brief [123] received from Amicus Curiae Iancu. [584550] [CJF] [Entered: 02/08/2019 03:03 PM] (0) |
| Feb 8, 2019 | 127 | NOTICE OF NON-COMPLIANCE: The submission of Appellants BTG International Limited, Janssen Biotech, Inc., Janssen Oncology, Inc. and Janssen Research & Development, LLC, Paper Copies - Corrected Confidential Opening Brief [125], is not in compliance with the rules of this court (see attached). Compliant documents due on 02/11/2019. Service as of this date by the Clerk of Court.[584577] [JAL] [Entered: 02/08/2019 04:08 PM] (1) |
| Feb 6, 2019 | 124 | Response to notice of oral argument from the Appellants BTG International Limited, Janssen Biotech, Inc., Janssen Oncology, Inc. and Janssen Research & Development, LLC. [583889] [19-1147] [Constantine Trela] [Entered: 02/06/2019 04:41 PM] (3) |
| Feb 1, 2019 | 119 | Entry of appearance for Joseph Matal as of counsel for Amicus Curiae Iancu. Service: 02/01/2019 by email. [582675] [19-1147] [Joseph Matal] [Entered: 02/01/2019 09:56 AM] (2) |
| Feb 1, 2019 | 120 | Entry of appearance for Scott R. McIntosh as of counsel for Amicus Curiae Iancu. Service: 02/01/2019 by email. [582734] [19-1147] [Scott McIntosh] [Entered: 02/01/2019 10:43 AM] (1) |
| Feb 1, 2019 | 121 | Entry of appearance for Mark R. Freeman as of counsel for Director, US Patent and Trademark Office. Service: 02/01/2019 by email. [582780] [19-1147] [Mark Freeman] [Entered: 02/01/2019 12:34 PM] (1) |
| Feb 1, 2019 | 122 | Entry of appearance for Jennifer L. Utrecht as of counsel for Amicus Curiae Iancu. Service: 02/01/2019 by email. [582789] [19-1147] [Jennifer Utrecht] [Entered: 02/01/2019 12:42 PM] (1) |
| Feb 1, 2019 | 123 | MODIFIED ENTRY: AMICUS CURIAE BRIEF FILED for Iancu. Number of Pages: 19. Service: 02/01/2019 by email. [582923]--[Edited 02/04/2019 by JAL - Compliance review complete] [Farheena Rasheed] [Entered: 02/01/2019 05:41 PM] (30) |
| Jan 24, 2019 | 117 | Entry of appearance for Frances M. Lynch as of counsel for Amicus Curiae Iancu. Service: 01/24/2019 by email. [580425] [19-1147] [Frances Lynch] [Entered: 01/24/2019 09:59 AM] (2) |
| Jan 24, 2019 | 118 | Entry of appearance for Robert J. McManus as of counsel for Amicus Curiae Iancu. Service: 01/24/2019 by email. [580429] [19-1147] [Robert McManus] [Entered: 01/24/2019 10:03 AM] (2) |
| Jan 22, 2019 | 112 | RESPONSE of Appellants BTG International Limited, Janssen Biotech, Inc., Janssen Oncology, Inc. and Janssen Research & Development, LLC to the motion to stay appeal [108] filed by Amicus Curiae Iancu, motion to extend time to file brief [108] filed by Amicus Curiae Iancu. Service: 01/21/2019 by email. [579498] [19-1147] [Constantine Trela] [Entered: 01/21/2019 01:11 PM] (12) |
| Jan 22, 2019 | 113 | NOTICE OF NON-COMPLIANCE: The submissions of Appellants BTG International Limited, Janssen Biotech, Inc., Janssen Oncology, Inc. and Janssen Research & Development, LLC, Opening Brief; Confidential Opening Brief [110], [111], are not in compliance with the rules of this court (see attached). Compliant documents due on 01/29/2019. Service as of this date by the Clerk of Court.[579543] [JAL] [Entered: 01/22/2019 09:23 AM] (2) |
| Jan 22, 2019 | 114 | ORDER filed denying [108] motion to stay appeal or extend time to file brief filed by Amicus Curiae Iancu. By: Clerk (Per Curiam). Service as of this date by the Clerk of Court. [579597] [JAL] [Entered: 01/22/2019 10:41 AM] (4) |
| Jan 22, 2019 | 115 | MODIFIED ENTRY: CORRECTED OPENING BRIEF FILED for Appellants BTG International Limited, Janssen Biotech, Inc., Janssen Oncology, Inc., and Janssen Research & Development, LLC. Number of Pages: 65. Service: 01/22/2019 by email. Unless ordered otherwise, any responsive deadline runs from the date of service of this brief. See Fed. Cir. R. 31. [579735]--[Edited 01/22/2019 by JAL - Compliance review complete] [Constantine Trela] [Entered: 01/22/2019 01:50 PM] (483) |
| Jan 22, 2019 | 116 | MODIFIED ENTRY: CORRECTED CONFIDENTIAL OPENING BRIEF FILED for Appellants BTG International Limited, Janssen Biotech, Inc., Janssen Oncology, Inc., and Janssen Research & Development, LLC. Number of Pages: 65. Service: 01/22/2019 by email. [579737]--[Edited 01/22/2019 by JAL - Compliance review complete] [Constantine Trela] [Entered: 01/22/2019 01:52 PM] (0) |
| Jan 18, 2019 | 109 | RESPONSE of Appellees Amneal Pharmaceuticals LLC, Amneal Pharmaceuticals of New York, LLC, Dr. Reddy's Laboratories, Inc., Dr. Reddy's Laboratories, Ltd., Wockhardt Bio AG, Wockhardt USA LLC, Wockhardt Ltd., Mylan Pharmaceuticals Inc., Mylan Inc., West-Ward Pharmaceuticals Corp., Hikma Pharmaceuticals LLC, Teva Pharmaceuticals USA, Inc., Amerigen Pharmaceuticals, Inc., Amerigen Pharmaceuticals Limited and Argentum Pharmaceuticals LLC to the motion [108] filed by Amicus Curiae Iancu, motion [108] filed by Amicus Curiae Iancu. Service: 01/18/2019 by email. [579394] [19-1147] [Dan Bagatell] [Entered: 01/18/2019 03:00 PM] (18) |
| Jan 18, 2019 | 110 | FILED from Appellants BTG International Limited, Janssen Biotech, Inc., Janssen Oncology, Inc. and Janssen Research & Development, LLC. Title: OPENING BRIEF. Service: 01/18/2019 by email. [579464] [19-1147] This document is non-compliant. See Doc No.[113] [Constantine Trela] [Entered: 01/18/2019 05:48 PM] (483) |
| Jan 18, 2019 | 111 | FILED from Appellants BTG International Limited, Janssen Biotech, Inc., Janssen Oncology, Inc. and Janssen Research & Development, LLC. Title: CONFIDENTIAL OPENING BRIEF. Service: 01/18/2019 by email, US mail. [579466] [19-1147] This document is non-compliant. See Doc No.[113] [Constantine Trela] [Entered: 01/18/2019 05:51 PM] (0) |
| Jan 17, 2019 | 106 | Entry of appearance for Thomas W. Krause as principal counsel for Amicus Curiae Iancu. Service: 01/17/2019 by email. [579031] [19-1147] [Thomas Krause] [Entered: 01/17/2019 03:09 PM] (2) |
| Jan 17, 2019 | 107 | Entry of appearance for Farheena Y. Rasheed as of counsel for Amicus Curiae Iancu. Service: 01/17/2019 by email. [579038] [19-1147] [Farheena Rasheed] [Entered: 01/17/2019 03:14 PM] (2) |
| Jan 17, 2019 | 108 | MOTION of Amicus Curiae Iancu to stay appeal, to extend the time to 02/15/2019 to file the Amicus Curiae Brief. [Consent: not addressed]. Service: 01/17/2019 by email. [579052] [19-1147] [Farheena Rasheed] [Entered: 01/17/2019 03:31 PM] (8) |
| Jan 16, 2019 | 103 | Notice to counsel for Appellee Argentum Pharmaceuticals LLC: The record of this case indicates that the Corrected Certificate of Interest has not been filed. A completed certificate of Interest must be submitted in accordance with Fed. Cir. R. 47.4 by 01/18/2019. Service as of this date by the Clerk of Court. [578430] [JAL] [Entered: 01/16/2019 10:07 AM] (0) |
| Jan 16, 2019 | 104 | Entry of appearance for Steven J. Horowitz as of counsel for Appellants Janssen Research & Development, LLC, Janssen Biotech, Inc. and Janssen Oncology, Inc.. Service: 01/16/2019 by email. [578569] [19-1147] [Steven Horowitz] [Entered: 01/16/2019 12:59 PM] (2) |
| Jan 16, 2019 | 105 | Corrected Certificate of Interest for the Appellee Argentum Pharmaceuticals LLC. Service: 01/16/2019 by email. [578634] [19-1147] [Teresa Rea] [Entered: 01/16/2019 03:06 PM] (3) |
| Jan 11, 2019 | 101 | ORDER scheduling oral argument. Service as of this date by the Clerk of Court. [577788] [JAB] [Entered: 01/11/2019 04:22 PM] (4) |
| Jan 11, 2019 | 102 | NOTICE OF ORAL ARGUMENT. Panel: 1903T. Case scheduled Mar 14, 2019 10:00 a.m. at the United States Court of Appeals for the Federal Circuit (Howard T. Markey National Courts Building, 717 Madison Place, NW Washington, DC 20439), Courtroom 201. Response to Notice of Oral Argument due: 02/15/2019. Please review the attached Notice. The response to notice of oral argument form can be found here. The Oral Argument Guide can be found here. [577790] [JAB] [Entered: 01/11/2019 04:24 PM] (2) |
| Jan 4, 2019 | 99 | ORDER filed granting motion to withdraw party [95] filed by Appellees Actavis Laboratories FL, Inc., Sun Pharmaceuticals Industries, Ltd and Sun Pharmaceuticals Industries Inc. Actavis Laboratories FL, Inc., Sun Pharmaceuticals Industries Inc. and Sun Pharmaceuticals Industries, Ltd are withdrawn as parties to these appeals. The revised official caption is reflected in the order. By: Clerk (Per Curiam). Service as of this date by the Clerk of Court. [575939] [JAL] [Entered: 01/04/2019 11:54 AM] (4) |
| Jan 4, 2019 | 100 | NOTICE OF NON-COMPLIANCE: The submission of Appellee Argentum Pharmaceuticals LLC, Certificate of Interest [97], is not in compliance with the rules of this court (see attached). Compliant document due on 01/11/2019. Service as of this date by the Clerk of Court.[575945] [JAL] [Entered: 01/04/2019 12:00 PM] (1) |
| Jan 3, 2019 | 94 | Certificate of Interest for the Appellees Actavis Laboratories FL, Inc., Sun Pharmaceuticals Industries Inc. and Sun Pharmaceuticals Industries, Ltd. Service: 01/03/2019 by email. [575786] [19-1147] [Charles Klein] [Entered: 01/03/2019 04:16 PM] (5) |
| Jan 3, 2019 | 95 | MOTION of Appellees Actavis Laboratories FL, Inc., Sun Pharmaceuticals Industries Inc. and Sun Pharmaceuticals Industries, Ltd to withdraw party, Actavis Laboratories FL, Inc., Sun Pharmaceuticals Industries, Ltd., and Sun Pharmaceuticals Industries Inc, as a party to this appeal [Consent: unopposed]. Service: 01/03/2019 by email. [575789] [19-1147] [Charles Klein] [Entered: 01/03/2019 04:24 PM] (7) |
| Jan 3, 2019 | 96 | Entry of appearance for Teresa Stanek Rea as principal counsel for Appellee Argentum Pharmaceuticals LLC. Service: 01/03/2019 by email. [575821] [19-1147] [Teresa Rea] [Entered: 01/03/2019 06:21 PM] (2) |
| Jan 3, 2019 | 97 | Certificate of Interest for the Appellee Argentum Pharmaceuticals LLC. Service: 01/03/2019 by email. [575822] [19-1147] This document is non-compliant. See Doc No.[100] [Teresa Rea] [Entered: 01/03/2019 06:23 PM] (3) |
| Jan 3, 2019 | 98 | Docketing Statement for the Appellee Argentum Pharmaceuticals LLC. Service: 01/03/2019 by email. [575823] [19-1147] [Teresa Rea] [Entered: 01/03/2019 06:25 PM] (4) |
| Jan 2, 2019 | 93 | Amended Entry of appearance for David L. Anstaett as of counsel for Appellees Mylan Inc. and Mylan Pharmaceuticals Inc.. Service: 01/02/2019 by clerk. [575201] [19-1147] [David Anstaett] [Entered: 01/02/2019 11:03 AM] (1) |
| Dec 28, 2018 | 92 | Amended Entry of appearance for Andrew T. Dufresne as of counsel for Appellees Mylan Inc. and Mylan Pharmaceuticals Inc.. Service: 12/28/2018 by clerk. [574940] [19-1147] [Andrew Dufresne] [Entered: 12/28/2018 11:49 AM] (1) |
| Dec 21, 2018 | 90 | MOTION of Cross-Appellants Mylan Inc., Mylan Pharmaceuticals Inc., Hikma Pharmaceuticals LLC, West-Ward Pharmaceuticals Corp. and Teva Pharmaceuticals USA, Inc. to voluntarily dismiss appeal pursuant to FRAP 42(b). [Consent: unopposed]. Service: 12/21/2018 by email. [573838] [19-1147] [Dan Bagatell] [Entered: 12/21/2018 08:58 AM] (9) |
| Dec 21, 2018 | 91 | ORDER granting motion to dismiss cross-appeals 19-1167 and 19-1236 pursuant to FRAP 42(b) [90] filed by Cross-Appellants Mylan Pharmaceuticals Inc., Teva Pharmaceuticals USA, Inc., Mylan Inc., West-Ward Pharmaceuticals Corp. and Hikma Pharmaceuticals LLC in 19-1147. Each side shall bear its own costs as to those appeals. The revised official caption for the remaining consolidated cases is reflected in the order. The revised briefing schedule is as follows: appellants’ consolidated principal brief is due no later than 01/18/19; the response of the Director of the USPTO is due no later than 02/01/19; appellees’ consolidated response brief is due no later than 02/15/19; appellants’ consolidated reply brief is due no later than 02/28/19; the consolidated joint appendix is due no later than 03/06/19. ISSUED AS MANDATE (as to 19-1167 and 19-1236 only). Service as of this date by the Clerk of Court. [574164] [19-1147, 19-1167, 19-1236] [JAL] [Entered: 12/21/2018 03:03 PM] (6) |
| Dec 20, 2018 | 86 | ORDER filed. The stay in the district court appeals is lifted. The district court appeals and the Board appeals are consolidated for purposes of briefing and argument. Each of the briefs shall include the full captions of the appeals as reflected above. The motion to exceed the word limit [84] is denied. The court strikes appellants’ opening brief [77] in the district court appeals filed on December 3, 2018 and sets the briefing schedule. (See order for more details). Cross-appellants are directed to inform this court no later than 12:00 p.m. on December 21, 2018 as to whether they wish to dismiss their cross-appeals. The USPTO is directed to transmit the certified lists within seven days from the date of filing of this order. (Per Curiam). Service: 12/20/2018 by clerk. [573472] [19-1147, 19-1148, 19-1167, 19-1236] [NL] [Entered: 12/20/2018 11:24 AM] (5) |
| Dec 20, 2018 | 87 | Note to file: The following cases are associated: 19-1147 Lead with 19-1323, 19-1324, and 19-1325 Member Cases. FURTHER ENTRIES WILL BE ADDED TO THE LEAD APPEAL ONLY. Entries of Appearance for Argentum Pharmaceuticals LLC, Actavis Laboratories FL, Inc., Sun Pharmaceuticals Industries, Ltd., Sun Pharmaceuticals Industries Inc., and Iancu due 01/03/2019. Certificates of Interest for Argentum Pharmaceuticals LLC, Actavis Laboratories FL, Inc., Sun Pharmaceuticals Industries, Ltd., and Sun Pharmaceuticals Industries Inc. due on 01/03/2019. Docketing Statements for Argentum Pharmaceuticals LLC, Actavis Laboratories FL, Inc., Sun Pharmaceuticals Industries, Ltd., and Sun Pharmaceuticals Industries Inc. due 01/03/2019. Appellants' consolidated principal brief is due 01/18/2019 [573591] [19-1147, 19-1323, 19-1324, 19-1325] [JAL] [Entered: 12/20/2018 02:41 PM] (0) |
| Dec 20, 2018 | 88 | REMINDER: All counsel of record are reminded of their responsibility per Fed. Cir. R. 47.4(a)and Fed. Cir. R. 47.3 to promptly submit an amended Certificate of Interest (COI) and/or Entry of Appearance (EOA) as information changes during the pendency of the appeal. Failure to comply with these Rules may delay the timely processing of your case or result in adverse action. [573605] [JAL] [Entered: 12/20/2018 02:59 PM] (0) |
| Dec 20, 2018 | 89 | NOTICE: Parties are hereby notified that paper copies of all briefs should be submitted immediately upon filing. [573610] [JAL] [Entered: 12/20/2018 03:03 PM] (0) |
| Dec 19, 2018 | 84 | MOTION of Appellants BTG International Limited, Janssen Biotech, Inc., Janssen Oncology, Inc. and Janssen Research & Development, LLC to waive the requirements regarding the brief (Appellants request an increase in the word limits for briefs set by Federal Circuit Rule 28.1(b) and 32(a).) [Consent: opposed]. Service: 12/19/2018 by email. [573039] [19-1147] [Constantine Trela] [Entered: 12/19/2018 12:36 PM] (244) |
| Dec 19, 2018 | 85 | Notice from Appellants BTG International Limited, Janssen Biotech, Inc., Janssen Oncology, Inc. and Janssen Research & Development, LLC Notice of Appeals from PTAB Decisions.. Service: 12/19/2018 by email. [573124] [19-1147] [Constantine Trela] [Entered: 12/19/2018 01:57 PM] (1) |
| Dec 12, 2018 | 82 | REPLY of Cross-Appellants Mylan Inc., Mylan Pharmaceuticals Inc. and Appellees Wockhardt Bio AG, Wockhardt Ltd., Wockhardt USA LLC, Amerigen Pharmaceuticals Limited and Amerigen Pharmaceuticals, Inc. to response filed by Appellants, Doc. No [81]. Service: 12/12/2018 by email. [571083] [19-1147] [Dan Bagatell] [Entered: 12/12/2018 08:31 AM] (9) |
| Dec 12, 2018 | 83 | ORDER filed. The motion [79] is granted to the extent that the briefing schedule set forth in this court’s November 20, 2018 order is vacated, and the briefing in these appeals is stayed pending further direction from the court. Upon receipt of the anticipated notices of appeals from the Board decisions, the court intends to consolidate these appeals and the Board appeals and to direct the USPTO to transmit the certified list within seven days from the docketing of the Board appeals. (Per Curiam). Service: 12/12/2018 by clerk. [571258] [NL] [Entered: 12/12/2018 12:10 PM] (4) |
| Dec 11, 2018 | 81 | RESPONSE of Appellants BTG International Limited, Janssen Biotech, Inc., Janssen Oncology, Inc. and Janssen Research & Development, LLC to the motion vacate [79] filed by Appellees Amerigen Pharmaceuticals Limited, Amerigen Pharmaceuticals, Inc., Amneal Pharmaceuticals LLC, Amneal Pharmaceuticals of New York, LLC, Dr. Reddy's Laboratories, Inc., Dr. Reddy's Laboratories, Ltd., Wockhardt Bio AG, Wockhardt USA LLC, Wockhardt Ltd. and Cross-Appellants Hikma Pharmaceuticals LLC, Teva Pharmaceuticals USA, Inc., Mylan Inc., Mylan Pharmaceuticals Inc. and West-Ward Pharmaceuticals Corp., motion to set briefing schedule [79] filed by Appellees Amerigen Pharmaceuticals Limited, Amerigen Pharmaceuticals, Inc., Amneal Pharmaceuticals LLC, Amneal Pharmaceuticals of New York, LLC, Dr. Reddy's Laboratories, Inc., Dr. Reddy's Laboratories, Ltd., Wockhardt Bio AG, Wockhardt USA LLC, Wockhardt Ltd. and Cross-Appellants Hikma Pharmaceuticals LLC, Teva Pharmaceuticals USA, Inc., Mylan Inc., Mylan Pharmaceuticals Inc. and West-Ward Pharmaceuticals Corp., motion to reschedule argument [79] filed by Appellees Amerigen Pharmaceuticals Limited, Amerigen Pharmaceuticals, Inc., Amneal Pharmaceuticals LLC, Amneal Pharmaceuticals of New York, LLC, Dr. Reddy's Laboratories, Inc., Dr. Reddy's Laboratories, Ltd., Wockhardt Bio AG, Wockhardt USA LLC, Wockhardt Ltd. and Cross-Appellants Hikma Pharmaceuticals LLC, Teva Pharmaceuticals USA, Inc., Mylan Inc., Mylan Pharmaceuticals Inc. and West-Ward Pharmaceuticals Corp.. Service: 12/11/2018 by email. [570910] [19-1147] [Constantine Trela] [Entered: 12/11/2018 01:52 PM] (20) |
| Dec 10, 2018 | 80 | ORDER filed. Any opposition to the motion [79] is due no later than 3:00 p.m. on December 11, 2018. Appellants are directed to propose an alternative briefing and argument schedule if this court were to grant this motion, vacate the current schedule, and make these appeals and any appeals from the related Board decisions companion cases.; If the parties wish to appeal from the Board’s final decisions in IPRs 2016-00286, 2016-01332, and 2016-01582, they shall file a notice of appeal no later than December 19, 2018 and immediately notify this court. See Fed. R. App. P. 2. The parties should anticipate expedited briefing and argument in any such appeal. (Per Curiam). Service: 12/10/2018 by clerk. [570472] [NL] [Entered: 12/10/2018 12:16 PM] (3) |
| Dec 7, 2018 | 79 | MOTION of Appellees Amerigen Pharmaceuticals Limited, Amerigen Pharmaceuticals, Inc., Amneal Pharmaceuticals LLC, Amneal Pharmaceuticals of New York, LLC, Dr. Reddy's Laboratories, Inc., Dr. Reddy's Laboratories, Ltd., Wockhardt Bio AG, Wockhardt USA LLC, Wockhardt Ltd. and Cross-Appellants Hikma Pharmaceuticals LLC, Teva Pharmaceuticals USA, Inc., Mylan Inc., Mylan Pharmaceuticals Inc. and West-Ward Pharmaceuticals Corp. to vacate the Paragraph (2) of the Court's order of November 20, 2018 (Dkt. 68).., to set briefing schedule, to reschedule argument [Consent: opposed]. Service: 12/07/2018 by clerk. [570325] [19-1147] [Andrew Dufresne] [Entered: 12/07/2018 04:41 PM] (20) |
| Dec 4, 2018 | 78 | RESPONSE of Appellees Amerigen Pharmaceuticals Limited, Amerigen Pharmaceuticals, Inc., Amneal Pharmaceuticals LLC, Amneal Pharmaceuticals of New York, LLC, Dr. Reddy's Laboratories, Inc., Dr. Reddy's Laboratories, Ltd., Hikma Pharmaceuticals LLC, Teva Pharmaceuticals USA, Inc., West-Ward Pharmaceuticals Corp., Wockhardt Bio AG, Wockhardt Ltd., Wockhardt USA LLC and Cross-Appellants Mylan Inc. and Mylan Pharmaceuticals Inc. to the court order vacate [68] , court order to set briefing schedule [68] , court order invite the PTO to participate as an amicus [68] , court order to schedule oral argument [68] , court order to allow argument [68] , court order [68]. Service: 12/04/2018 by email. [569618] [19-1147] [Dan Bagatell] [Entered: 12/04/2018 02:56 PM] (26) |
| Dec 3, 2018 | 77 | MODIFIED ENTRY: BRIEF FILED for Appellants BTG International Limited, Janssen Biotech, Inc., Janssen Oncology, Inc. and Janssen Research & Development, LLC. Number of Pages: 63. Service: 12/03/2018 by email. Unless ordered otherwise, any responsive deadline runs from the date of service of this brief. See Fed. Cir. R. 31. [569440] --[Edited 12/04/2018 by JAL - Compliance review complete] "Stricken pursuant to the court's order. See Doc. No. [86]" [Constantine Trela] [Entered: 12/03/2018 05:34 PM] (0) |
| Nov 30, 2018 | 76 | Entry of appearance for Ryan B. Hauer as of counsel for Appellees Amneal Pharmaceuticals LLC, Amneal Pharmaceuticals of New York, LLC, Dr. Reddy's Laboratories, Inc., Dr. Reddy's Laboratories, Ltd., Teva Pharmaceuticals USA, Inc., West-Ward Pharmaceuticals Corp. and Hikma Pharmaceuticals LLC. Service: 11/30/2018 by email. [568942] [19-1147] [Ryan Hauer] [Entered: 11/30/2018 01:33 PM] (2) |
| Nov 29, 2018 | 75 | Amended Transcript Purchase Order Form for the Appellants BTG International Limited, Janssen Biotech, Inc., Janssen Oncology, Inc., and Janssen Research & Development, LLC indicating that a request is made to the reporter for a transcript. Service: 11/29/2018 by clerk. [568539] [JAL] [Entered: 11/29/2018 12:43 PM] (1) |
| Nov 27, 2018 | 73 | Official caption revised to reflect second cross-appeal. The official caption is reflected on the electronic docket under the listing of the parties and counsel. Service as of this date by the Clerk of Court. [567952] [JAL] [Entered: 11/27/2018 03:40 PM] (0) |
| Nov 27, 2018 | 74 | Clerk's Note to the File: The following cases are associated: 19-1147 Lead with 19-1236 Cross-Appeal Member Case. FURTHER ENTRIES WILL BE ADDED TO THE LEAD APPEAL ONLY. [567953] [19-1147, 19-1236] [JAL] [Entered: 11/27/2018 03:42 PM] (0) |
| Nov 21, 2018 | 72 | ORDER filed denying [71] motion for temporary injunction pending appeal filed by BTG International Limited, Janssen Biotech, Inc., Janssen Oncology, Inc., and Janssen Research & Development, LLC. By: Per Curiam. Service as of this date by the Clerk of Court. [567112] [CAB] [Entered: 11/21/2018 11:49 AM] (3) |
| Nov 20, 2018 | 68 | ORDER filed. The motion for an injunction [12] is denied. This court’s temporary injunction is vacated. See order for briefing schedule. Oral argument is scheduled for 01/24/2019. The parties are directed to notify the court as soon as PTAB issues reconsideration decisions in IPRs 2016-00286, 2016-01332, and 2016-01582. The court invites the Director of the United States Patent and Trademark Office for his views. The Director may file an amicus brief in accordance with this order by 12/19/2018 and will be given five minutes of oral argument time. By: Motions Panel (Per Curiam). Service as of this date by the Clerk of Court. [566883] [JAB] [Entered: 11/20/2018 03:49 PM] (4) |
| Nov 20, 2018 | 69 | NOTICE OF ORAL ARGUMENT. Panel: 1901P. Case scheduled Jan 24, 2019 10:00 a.m. at the United States Court of Appeals for the Federal Circuit (Howard T. Markey National Courts Building, 717 Madison Place, NW Washington, DC 20439), Courtroom 201. Response to Notice of Oral Argument due: 12/17/2018. Please review the attached Notice. The response to notice of oral argument form can be found here. The Oral Argument Guide can be found here. [566897] [JAB] [Entered: 11/20/2018 04:02 PM] (2) |
| Nov 20, 2018 | 70 | ORDER filed. The motion to waive the requirements of Federal Circuit Rule 27 [15] and the motion for leave to file three declarations [45] are granted. (Per Curiam). Service: 11/20/2018 by clerk. [566917] [NL] [Entered: 11/20/2018 04:41 PM] (3) |
| Nov 20, 2018 | 71 | MOTION of Appellants BTG International Limited, Janssen Biotech, Inc., Janssen Oncology, Inc. and Janssen Research & Development, LLC for temporary injunction [Consent: not addressed]. Service: 11/20/2018 by email. [566968] [19-1147] [Constantine Trela] [Entered: 11/20/2018 07:21 PM] (13) |
| Nov 16, 2018 | 67 | Transcript Purchase Order Form for the Appellants BTG International Limited, Janssen Biotech, Inc., Janssen Oncology, Inc. and Janssen Research & Development, LLC indicating that a request is made to the reporter for a transcript. Service: 11/16/2018 by clerk. [565758] [JAL] [Entered: 11/16/2018 10:50 AM] (1) |
| Nov 15, 2018 | 59 | Docketing Statement for the Appellant BTG International Limited. Service: 11/15/2018 by email. [565328] [19-1147] [Constantine Trela] [Entered: 11/15/2018 01:30 PM] (5) |
| Nov 15, 2018 | 60 | Certificate of Interest for the Appellant BTG International Limited. Service: 11/15/2018 by email. [565329] [19-1147] [Constantine Trela] [Entered: 11/15/2018 01:30 PM] (6) |
| Nov 15, 2018 | 61 | Docketing Statement for the Appellants Janssen Biotech, Inc., Janssen Oncology, Inc. and Janssen Research & Development, LLC. Service: 11/15/2018 by email. [565331] [19-1147] [Constantine Trela] [Entered: 11/15/2018 01:31 PM] (3) |
| Nov 15, 2018 | 62 | Certificate of Interest for the Appellants Janssen Biotech, Inc., Janssen Oncology, Inc. and Janssen Research & Development, LLC. Service: 11/15/2018 by email. [565333] [19-1147] [Constantine Trela] [Entered: 11/15/2018 01:32 PM] (5) |
| Nov 15, 2018 | 63 | Docketing Statement for the Cross-Appellants Mylan Inc. and Mylan Pharmaceuticals Inc.. Service: 11/15/2018 by email. [565629] [19-1147] [Dan Bagatell] [Entered: 11/15/2018 06:11 PM] (2) |
| Nov 15, 2018 | 64 | Docketing Statement for the Appellees Wockhardt Bio AG, Wockhardt Ltd. and Wockhardt USA LLC. Service: 11/15/2018 by email. [565639] [19-1147] [Jon Wright] [Entered: 11/15/2018 07:19 PM] (5) |
| Nov 15, 2018 | 65 | Docketing Statement for the Appellees Amerigen Pharmaceuticals Limited and Amerigen Pharmaceuticals, Inc.. Service: 11/15/2018 by email. [565645] [19-1147] [Christopher Casieri] [Entered: 11/15/2018 09:27 PM] (3) |
| Nov 15, 2018 | 66 | Docketing Statement for the Appellees Amneal Pharmaceuticals LLC, Amneal Pharmaceuticals of New York, LLC, Dr. Reddy's Laboratories, Inc., Dr. Reddy's Laboratories, Ltd., Teva Pharmaceuticals USA, Inc., West-Ward Pharmaceuticals Corp. and Hikma Pharmaceuticals LLC. Service: 11/15/2018 by email. [565649] [19-1147] [Charles Klein] [Entered: 11/15/2018 11:38 PM] (3) |
| Nov 13, 2018 | 58 | Corrected Certificate of Interest for the Appellees Amerigen Pharmaceuticals Limited and Amerigen Pharmaceuticals, Inc.. Service: 11/13/2018 by email. [564651] [19-1147] [William Hare] [Entered: 11/13/2018 06:05 PM] (2) |
| Nov 8, 2018 | 56 | Amended Entry of appearance for Anthony C. Tridico as principal counsel for Appellant BTG International Limited. Service: 11/08/2018 by email. [563469] [19-1147] [Constantine Trela] [Entered: 11/08/2018 09:55 AM] (2) |
| Nov 8, 2018 | 57 | Sealed or confidential document received [CORRECTED REPLY IN SUPPORT OF EMERGENCY MOTION OF PLAINTIFFS-APPELLANTS BTG INTERNATIONAL, LTD., JANSSEN BIOTECH, INC., JANSSEN ONCOLOGY, INC., AND JANSSEN RESEARCH & DEVELOPMENT, LLC UNDER FED. R. APP. P. 8(a) FOR AN INJUNCTION PENDING APPEAL] (corresponding to Doc No. [51]) for Appellants BTG International Limited, Janssen Biotech, Inc., Janssen Oncology, Inc. and Janssen Research & Development, LLC. Service: 11/08/2018 by email. [563473] [19-1147] [Constantine Trela] [Entered: 11/08/2018 10:02 AM] (0) |
| Nov 7, 2018 | 51 | REPLY of Appellants BTG International Limited, Janssen Biotech, Inc., Janssen Oncology, Inc. and Janssen Research & Development, LLC to response filed by Appellees, Doc. No [48]. Service: 11/07/2018 by email. [563210] [19-1147] [Constantine Trela] [Entered: 11/07/2018 11:52 AM] (84) |
| Nov 7, 2018 | 52 | Sealed or confidential document received [CONFIDENTIAL REPLY IN SUPPORT OF EMERGENCY MOTION OF PLAINTIFFS-APPELLANTS BTG INTERNATIONAL, LTD., JANSSEN BIOTECH, INC., JANSSEN ONCOLOGY, INC., AND JANSSEN RESEARCH & DEVELOPMENT, LLC UNDER FED. R. APP. P. 8(a) FOR AN INJUNCTION PENDING APPEAL] (corresponding to Doc No. [48]) for Appellants BTG International Limited, Janssen Biotech, Inc., Janssen Oncology, Inc. and Janssen Research & Development, LLC. Service: 11/07/2018 by email. [563212] [19-1147] This document is non-compliant. See Doc No.[53] [Constantine Trela] [Entered: 11/07/2018 11:55 AM] (0) |
| Nov 7, 2018 | 53 | NOTICE OF NON-COMPLIANCE: The submission of Appellants BTG International Limited, Janssen Biotech, Inc., Janssen Oncology, Inc., and Janssen Research & Development, LLC, Confidential Reply in Support of Emergency Motion [52], is not in compliance with the rules of this court (see attached). Compliant document due on 11/15/2018. Service as of this date by the Clerk of Court.[563292] [JAL] [Entered: 11/07/2018 02:20 PM] (2) |
| Nov 7, 2018 | 54 | Clerk's Note to the File: The following cases are associated: 19-1147 Lead with 19-1167 Cross-Appeal Member Case. FURTHER ENTRIES WILL BE ADDED TO THE LEAD APPEAL ONLY. [563364] [19-1147, 19-1167] [JAL] [Entered: 11/07/2018 03:51 PM] (0) |
| Nov 7, 2018 | 55 | Official caption revised to reflect cross-appeal. The official caption is reflected on the electronic docket under the listing of the parties and counsel. Service as of this date by the Clerk of Court. [563381] [JAL] [Entered: 11/07/2018 04:05 PM] (0) |
| Nov 6, 2018 | 49 | Entry of appearance for DENNIES VARUGHESE as principal counsel for Appellees Wockhardt Bio AG, Wockhardt Ltd. and Wockhardt USA LLC. Service: 11/06/2018 by email. [563057] [19-1147] [Dennies Varughese] [Entered: 11/06/2018 04:24 PM] (2) |
| Nov 6, 2018 | 50 | Amended Certificate of Interest for the Appellees Wockhardt Bio AG, Wockhardt Ltd. and Wockhardt USA LLC. Service: 11/06/2018 by email. [563058] [19-1147] [Dennies Varughese] [Entered: 11/06/2018 04:26 PM] (3) |
| Nov 5, 2018 | 34 | Certificate of Interest for the Appellees Amneal Pharmaceuticals LLC, Amneal Pharmaceuticals of New York, LLC, Dr. Reddy's Laboratories, Inc., Dr. Reddy's Laboratories, Ltd., Hikma Pharmaceuticals LLC, Teva Pharmaceuticals USA, Inc. and West-Ward Pharmaceuticals Corp.. Service: 11/03/2018 by email. [562421] [19-1147] [Charles Klein] [Entered: 11/03/2018 02:34 PM] (5) |
| Nov 5, 2018 | 35 | CLERK'S OFFICE QUALITY CONTROL MESSAGE: re:attorney entry of appearance Docket No. [32], attorney entry of appearance Docket No. [30], ERROR: The contact information contained on the entries of appearance for Dennies Varughese [32] and Jon E. Wright [30] does not match the contact information in the attorneys' user accounts. CORRECTION: Please update as needed to ensure the contact information on the entries of appearance and in the user accounts matches. THIS MESSAGE IS FOR INFORMATIONAL PURPOSES ONLY. [562489] [JAL] [Entered: 11/05/2018 10:11 AM] (0) |
| Nov 5, 2018 | 36 | NOTICE OF NON-COMPLIANCE: The submission of Appellees Wockhardt Bio AG, Wockhardt Ltd. and Wockhardt USA LLC, Certificate of Interest [31], is not in compliance with the rules of this court (see attached). Compliant document due on 11/13/2018. Service as of this date by the Clerk of Court.[562490] [JAL] [Entered: 11/05/2018 10:12 AM] (2) |
| Nov 5, 2018 | 37 | Certificate of Interest for the Appellees Amerigen Pharmaceuticals Limited and Amerigen Pharmaceuticals, Inc.. Service: 11/05/2018 by email. [562507] [19-1147] This document is non-compliant. See Doc No.[41] [William Hare] [Entered: 11/05/2018 10:45 AM] (2) |
| Nov 5, 2018 | 38 | Entry of appearance for William D. Hare as principal counsel for Appellees Amerigen Pharmaceuticals Limited and Amerigen Pharmaceuticals, Inc.. Service: 11/05/2018 by email. [562511] [19-1147] [William Hare] [Entered: 11/05/2018 10:47 AM] (1) |
| Nov 5, 2018 | 39 | Entry of appearance for Christopher Casieri as of counsel for Appellees Amerigen Pharmaceuticals Limited and Amerigen Pharmaceuticals, Inc.. Service: 11/05/2018 by email. [562513] [19-1147] [William Hare] [Entered: 11/05/2018 10:49 AM] (1) |
| Nov 5, 2018 | 40 | MOTION of Appellees Amneal Pharmaceuticals LLC, Amneal Pharmaceuticals of New York, LLC, Dr. Reddy's Laboratories, Inc., Dr. Reddy's Laboratories, Ltd., West-Ward Pharmaceuticals Corp., Teva Pharmaceuticals USA, Inc. and Hikma Pharmaceuticals LLC Unopposed Emergency Motion to Amend Temporary Injunction [Consent: unopposed]. Service: 11/05/2018 by email. [562525] [19-1147] [Charles Klein] [Entered: 11/05/2018 11:00 AM] (16) |
| Nov 5, 2018 | 41 | NOTICE OF NON-COMPLIANCE: The submission of Appellees Amerigen Pharmaceuticals Limited and Amerigen Pharmaceuticals, Inc., Certificate of Interest [37], is not in compliance with the rules of this court (see attached). Compliant document due on 11/13/2018. Service as of this date by the Clerk of Court.[562530] [JAL] [Entered: 11/05/2018 11:03 AM] (2) |
| Nov 5, 2018 | 42 | CLERK'S OFFICE QUALITY CONTROL MESSAGE: re:attorney entry of appearance Docket No. [39], attorney entry of appearance Docket No. [38], ERROR: Only the lead case of a consolidated group was listed. CORRECTION: For future filings, please list the lead case (19-1147) as well as any member cases of a consolidated group (19-1148). THIS MESSAGE IS FOR INFORMATIONAL PURPOSES ONLY. [562532] [JAL] [Entered: 11/05/2018 11:07 AM] (0) |
| Nov 5, 2018 | 43 | RESPONSE of Appellees Amerigen Pharmaceuticals Limited, Amerigen Pharmaceuticals, Inc., Amneal Pharmaceuticals LLC, Amneal Pharmaceuticals of New York, LLC, Dr. Reddy's Laboratories, Inc., Dr. Reddy's Laboratories, Ltd., Hikma Pharmaceuticals LLC, Mylan Inc., Mylan Pharmaceuticals Inc., Teva Pharmaceuticals USA, Inc., West-Ward Pharmaceuticals Corp., Wockhardt Bio AG, Wockhardt Ltd. and Wockhardt USA LLC to the motion for stay pending appeal under Rule 8/18 [12] filed by Appellants BTG International Limited, Janssen Biotech, Inc., Janssen Oncology, Inc. and Janssen Research & Development, LLC. Service: 11/05/2018 by email. [562654] [19-1147] This document has been corrected. See Doc No. [48].--[Edited 11/08/2018 by CAB to revise docket text] [Dan Bagatell] [Entered: 11/05/2018 02:47 PM] (0) |
| Nov 5, 2018 | 44 | Sealed or confidential document received [Appellees' Confidential Response to Appellants' Motion for an Injunction Pending Appeal] (corresponding to Doc No. [43]) for Appellees Amerigen Pharmaceuticals Limited, Amerigen Pharmaceuticals, Inc., Amneal Pharmaceuticals LLC, Amneal Pharmaceuticals of New York, LLC, Dr. Reddy's Laboratories, Inc., Dr. Reddy's Laboratories, Ltd., Hikma Pharmaceuticals LLC, Mylan Inc., Mylan Pharmaceuticals Inc., Teva Pharmaceuticals USA, Inc., West-Ward Pharmaceuticals Corp., Wockhardt Bio AG, Wockhardt Ltd. and Wockhardt USA LLC. Service: 11/05/2018 by email. [562656] [19-1147] [Dan Bagatell] [Entered: 11/05/2018 02:50 PM] (0) |
| Nov 5, 2018 | 45 | MOTION of Appellees Amerigen Pharmaceuticals Limited, Amerigen Pharmaceuticals, Inc., Amneal Pharmaceuticals LLC, Amneal Pharmaceuticals of New York, LLC, Dr. Reddy's Laboratories, Inc., Dr. Reddy's Laboratories, Ltd., Hikma Pharmaceuticals LLC, Mylan Inc., Mylan Pharmaceuticals Inc., Teva Pharmaceuticals USA, Inc., West-Ward Pharmaceuticals Corp., Wockhardt Bio AG, Wockhardt Ltd. and Wockhardt USA LLC Leave to File Confidential and Redacted Non-Confidential Versions of the Declarations of Keith Meckstroth, Sunil Khera, and Ivan Hofmann Attached to Appellees' Response to Appellants' Motion for Injunction Pending Appeal [Consent: not addressed]. Service: 11/05/2018 by email. [562659] [19-1147] [Dan Bagatell] [Entered: 11/05/2018 02:58 PM] (18) |
| Nov 5, 2018 | 46 | ORDER filed. Upon consideration of Appellees' unopposed motion to modify the portion of this court's November 2, 2018 order (ECF No. 29) that granted a temporary injunction, IT IS ORDERED THAT: Paragraph (2) of ECF No. 29 is vacated and replaced with the following: (2) We grant Appellants' request for a temporary injunction to the extent that: (a) Appellees, their officers, agents, servants, employees, attorneys, and other persons who are in active concert or participation with the foregoing, including but not limited to all U.S. distribution partners for Appellees' generic versions of Appellants' ZYTIGA drug product, are enjoined from entering into any binding offer for sale for any and all generic copies of ZYTIGA, and sale of any and all generic copies of ZYTIGA, until this court renders a decision on Appellants' motion under Fed. R. App. P. 8 for an injunction pending a decision by this court on the merits of these appeals (ECF No. 13); and (b) Appellants shall not enter into any binding offer for sale for an authorized generic product until this order is no longer in effect or until this court renders a decision on Appellants' motion under Fed. R. App. P. 8 for an injunction pending a decision by this court on the merits of these appeals (ECF No. 13), whichever is sooner. (Per Curiam). Service: 11/05/2018 by clerk. [562670] The temporary injunction has been vacated. See order [68]. [LMS] [Entered: 11/05/2018 03:16 PM] (3) |
| Nov 5, 2018 | 47 | Notice of Correction to the response Doc No. [43] for Appellees Mylan Inc. and Mylan Pharmaceuticals Inc.. Service: 11/05/2018 by email. [562697] [19-1147] [Dan Bagatell] [Entered: 11/05/2018 04:20 PM] (4) |
| Nov 5, 2018 | 48 | RESPONSE of Appellees Amerigen Pharmaceuticals Limited, Amerigen Pharmaceuticals, Inc., Amneal Pharmaceuticals LLC, Amneal Pharmaceuticals of New York, LLC, Dr. Reddy's Laboratories, Inc., Dr. Reddy's Laboratories, Ltd., Hikma Pharmaceuticals LLC, Mylan Inc., Mylan Pharmaceuticals Inc., Teva Pharmaceuticals USA, Inc., West-Ward Pharmaceuticals Corp., Wockhardt Bio AG, Wockhardt Ltd. and Wockhardt USA LLC to the motion for stay pending appeal under Rule 8/18 [12] filed by Appellants BTG International Limited, Janssen Biotech, Inc., Janssen Oncology, Inc. and Janssen Research & Development, LLC. Service: 11/05/2018 by email. [562698] [19-1147] [Dan Bagatell] [Entered: 11/05/2018 04:24 PM] (182) |
| Nov 2, 2018 | 16 | Entry of appearance for Andrew T. Dufresne as of counsel for Appellees Mylan Inc. and Mylan Pharmaceuticals Inc.. Service: 11/02/2018 by clerk. [562108] [19-1147] [Andrew Dufresne] [Entered: 11/02/2018 09:05 AM] (1) |
| Nov 2, 2018 | 17 | RESPONSE of Appellees Mylan Inc. and Mylan Pharmaceuticals Inc. to the motion to expedite other [14] filed by Appellants BTG International Limited, Janssen Biotech, Inc., Janssen Oncology, Inc. and Janssen Research & Development, LLC. Service: 11/02/2018 by clerk. [562117] [19-1147] --[Edited 11/02/2018 by CAB to revise docket text] [Andrew Dufresne] [Entered: 11/02/2018 09:27 AM] (8) |
| Nov 2, 2018 | 18 | Certificate of Interest for the Appellees Mylan Inc. and Mylan Pharmaceuticals Inc.. Service: 11/02/2018 by clerk. [562138] [19-1147] [Andrew Dufresne] [Entered: 11/02/2018 10:03 AM] (4) |
| Nov 2, 2018 | 19 | Entry of appearance for Brandon M. White as of counsel for Appellees Mylan Pharmaceuticals Inc. and Mylan Inc.. Service: 11/02/2018 by clerk. [562143] [19-1147] [Andrew Dufresne] [Entered: 11/02/2018 10:10 AM] (2) |
| Nov 2, 2018 | 20 | Entry of appearance for Dan L. Bagatell as principal counsel for Appellees Mylan Pharmaceuticals Inc. and Mylan Inc.. Service: 11/02/2018 by clerk. [562147] [19-1147] [Andrew Dufresne] [Entered: 11/02/2018 10:17 AM] (2) |
| Nov 2, 2018 | 21 | Entry of appearance for Shannon M. Bloodworth as of counsel for Appellees Mylan Inc. and Mylan Pharmaceuticals Inc.. Service: 11/02/2018 by clerk. [562148] [19-1147] [Andrew Dufresne] [Entered: 11/02/2018 10:21 AM] (2) |
| Nov 2, 2018 | 22 | Entry of appearance for Charles B. Klein as principal counsel for Appellees Amneal Pharmaceuticals LLC, Amneal Pharmaceuticals of New York, LLC, Dr. Reddy's Laboratories, Inc., Dr. Reddy's Laboratories, Ltd., Teva Pharmaceuticals USA, Inc., West-Ward Pharmaceuticals Corp. and Hikma Pharmaceuticals LLC. Service: 11/02/2018 by email. [562167] [19-1147] [Charles Klein] [Entered: 11/02/2018 10:54 AM] (2) |
| Nov 2, 2018 | 23 | Entry of appearance for Andrew C. Nichols as of counsel for Appellees Amneal Pharmaceuticals LLC, Amneal Pharmaceuticals of New York, LLC, Dr. Reddy's Laboratories, Inc., Dr. Reddy's Laboratories, Ltd., Teva Pharmaceuticals USA, Inc., West-Ward Pharmaceuticals Corp. and Hikma Pharmaceuticals LLC. Service: 11/02/2018 by email. [562169] [19-1147] [Andrew Nichols] [Entered: 11/02/2018 10:58 AM] (2) |
| Nov 2, 2018 | 24 | Entry of appearance for Jovial Wong as of counsel for Appellees Amneal Pharmaceuticals LLC, Amneal Pharmaceuticals of New York, LLC, Dr. Reddy's Laboratories, Inc., Dr. Reddy's Laboratories, Ltd., Teva Pharmaceuticals USA, Inc., West-Ward Pharmaceuticals Corp. and Hikma Pharmaceuticals LLC. Service: 11/02/2018 by email. [562171] [19-1147] [Jovial Wong] [Entered: 11/02/2018 11:00 AM] (2) |
| Nov 2, 2018 | 25 | Official caption revised to correct spelling of Appellant BTG International Limited's name. The official caption is reflected on the electronic docket under the listing of the parties and counsel. Service as of this date by the Clerk of Court. [562230] [CAB] [Entered: 11/02/2018 12:03 PM] (0) |
| Nov 2, 2018 | 26 | Entry of appearance for David L. Anstaett as of counsel for Appellees Mylan Inc. and Mylan Pharmaceuticals Inc.. Service: 11/02/2018 by clerk. [562241] [19-1147] [Andrew Dufresne] [Entered: 11/02/2018 12:33 PM] (2) |
| Nov 2, 2018 | 27 | CLERK'S OFFICE QUALITY CONTROL MESSAGE: re:attorney entry of appearance Docket No. [11], attorney entry of appearance Docket No. [10], attorney entry of appearance Docket No. [9], attorney entry of appearance Docket No. [8], attorney entry of appearance Docket No. [7], attorney entry of appearance Docket No. [6], attorney entry of appearance Docket No. [5], attorney entry of appearance Docket No. [4], attorney entry of appearance Docket No. [3], ERROR: Counsel listed consolidated case numbers as "19-1147 et al." CORRECTION: For future filings, please list both the lead case (19-1147) and any member cases (19-1148) of the consolidated group. THIS MESSAGE IS FOR INFORMATIONAL PURPOSES ONLY. [562260] [JAL] [Entered: 11/02/2018 01:23 PM] (0) |
| Nov 2, 2018 | 28 | CLERK'S OFFICE QUALITY CONTROL MESSAGE: re:attorney entry of appearance Docket No. [11], attorney entry of appearance Docket No. [8], ERROR: The contact information contained on the entries of appearance for Anthony C. Tridico [8] and Alyssa Hjemdahl-Monsen [11] does not match the contact information in the attorneys user accounts. CORRECTION: Please update as needed to ensure the contact information on the entries of appearance and in the user accounts matches. THIS MESSAGE IS FOR INFORMATIONAL PURPOSES ONLY. [562262] [JAL] [Entered: 11/02/2018 01:26 PM] (0) |
| Nov 2, 2018 | 29 | ORDER filed. The motion to expedite [14] is granted to the extent that Appellees are directed to respond to the motion for an injunction pending appeal [12] no later than 3:00 p.m. Eastern time on November 5, 2018. Any reply in support of the motion is due no later 12:00 noon Eastern time on November 7, 2018., The same deadlines apply for the response and reply to the motion to waive the requirements of Fed. Cir. R. 27(m)(1) [15].; We grant Appellants’ request for a temporary injunction to the extent that Defendants are prohibited from marketing, selling, offering to sell, or importing into the United States any generic version of Appellants’ branded product ZYTIGA® pending this court’s ruling on the motion for an injunction pending appeal or further notice of the court. (Per Curiam). Service: 11/02/2018 by clerk. [562364] The temporary injunction has been vacated. See order [68]. [NL] [Entered: 11/02/2018 04:11 PM] (4) |
| Nov 2, 2018 | 30 | Entry of appearance for Jon E. Wright as of counsel for Appellees Wockhardt Bio AG, Wockhardt USA LLC and Wockhardt Ltd.. Service: 11/02/2018 by email. [562404] [19-1147] [Jon Wright] [Entered: 11/02/2018 06:30 PM] (2) |
| Nov 2, 2018 | 31 | Certificate of Interest for the Appellees Wockhardt Bio AG, Wockhardt Ltd. and Wockhardt USA LLC. Service: 11/02/2018 by email. [562406] [19-1147] This document is non-compliant. See Doc No.[36] [Jon Wright] [Entered: 11/02/2018 06:31 PM] (3) |
| Nov 2, 2018 | 32 | Entry of appearance for Dennies Varughese as principal counsel for Appellees Wockhardt Bio AG, Wockhardt Ltd. and Wockhardt USA LLC. Service: 11/02/2018 by email. [562407] [19-1147] [Jon Wright] [Entered: 11/02/2018 06:34 PM] (2) |
| Nov 2, 2018 | 33 | Entry of appearance for Daniel Ritterbeck as of counsel for Appellees Wockhardt Bio AG, Wockhardt Ltd. and Wockhardt USA LLC. Service: 11/02/2018 by email. [562408] [19-1147] [Jon Wright] [Entered: 11/02/2018 06:36 PM] (2) |
| Nov 1, 2018 | 1 | Appeal docketed. Received: 10/31/2018. [561960]Entry of Appearance due 11/15/2018. Certificate of Interest is due on 11/15/2018. Docketing Statement due 11/15/2018. Appellant/Petitioner's brief is due 12/31/2018. [JAL] [Entered: 11/01/2018 02:42 PM] (169) |
| Nov 1, 2018 | 2 | Clerk's Note to the File: The following cases are associated: 19-1147 Lead with 19-1148 Member Case. FURTHER ENTRIES WILL BE ADDED TO THE LEAD APPEAL ONLY. [561977] [19-1147, 19-1148] [JAL] [Entered: 11/01/2018 03:11 PM] (0) |
| Nov 1, 2018 | 3 | Entry of appearance for Constantine L. Trela, Jr. as principal counsel for Appellants Janssen Biotech, Inc., Janssen Oncology, Inc. and Janssen Research & Development, LLC. Service: 11/01/2018 by email. [562046] [19-1147] [Constantine Trela] [Entered: 11/01/2018 04:50 PM] (3) |
| Nov 1, 2018 | 4 | Entry of appearance for Carter G. Phillips as of counsel for Appellants Janssen Biotech, Inc., Janssen Oncology, Inc. and Janssen Research & Development, LLC. Service: 11/01/2018 by email. [562047] [19-1147] [Constantine Trela] [Entered: 11/01/2018 04:52 PM] (3) |
| Nov 1, 2018 | 5 | Entry of appearance for Thomas D. Rein as of counsel for Appellants Janssen Biotech, Inc., Janssen Oncology, Inc. and Janssen Research & Development, LLC. Service: 11/01/2018 by email. [562050] [19-1147] [Constantine Trela] [Entered: 11/01/2018 04:55 PM] (3) |
| Nov 1, 2018 | 6 | Entry of appearance for David T. Pritikin as of counsel for Appellants Janssen Biotech, Inc., Janssen Oncology, Inc. and Janssen Research & Development, LLC. Service: 11/01/2018 by email. [562052] [19-1147] [Constantine Trela] [Entered: 11/01/2018 04:57 PM] (3) |
| Nov 1, 2018 | 7 | Entry of appearance for Ryan C. Morris as of counsel for Appellants Janssen Biotech, Inc., Janssen Oncology, Inc. and Janssen Research & Development, LLC. Service: 11/01/2018 by email. [562054] [19-1147] [Constantine Trela] [Entered: 11/01/2018 04:59 PM] (3) |
| Nov 1, 2018 | 8 | Entry of appearance for Anthony C. Tridico as principal counsel for Appellant BTG International Limited. Service: 11/01/2018 by email. [562056] [19-1147] --[Edited 11/02/2018 by CAB to revise docket text] [Constantine Trela] [Entered: 11/01/2018 05:04 PM] (3) |
| Nov 1, 2018 | 9 | Entry of appearance for Jennifer H. Roscetti as of counsel for Appellant BTG International Limited. Service: 11/01/2018 by email. [562057] [19-1147] --[Edited 11/02/2018 by CAB to revise docket text] [Constantine Trela] [Entered: 11/01/2018 05:06 PM] (3) |
| Nov 1, 2018 | 10 | Entry of appearance for Paul Zegger as of counsel for Appellants Janssen Biotech, Inc., Janssen Oncology, Inc. and Janssen Research & Development, LLC. Service: 11/01/2018 by email. [562058] [19-1147] [Constantine Trela] [Entered: 11/01/2018 05:09 PM] (3) |
| Nov 1, 2018 | 11 | Entry of appearance for Alyssa Hjemdahl-Monsen as of counsel for Appellants Janssen Biotech, Inc., Janssen Oncology, Inc. and Janssen Research & Development, LLC. Service: 11/01/2018 by email. [562059] [19-1147] [Constantine Trela] [Entered: 11/01/2018 05:10 PM] (3) |
| Nov 1, 2018 | 12 | MOTION of Appellants BTG International Limited, Janssen Biotech, Inc., Janssen Oncology, Inc. and Janssen Research & Development, LLC for an emergency stay pending appeal under Rule 8/18 [Consent: opposed]. Service: 11/01/2018 by email. [562064] [19-1147] --[Edited 11/02/2018 by CAB to revise docket text] [Constantine Trela] [Entered: 11/01/2018 05:31 PM] (839) |
| Nov 1, 2018 | 13 | Sealed or confidential document received [Confidential Emergency Motion of Plaintiffs-Appellants BTG Int'l Ltd., Janssen Biotech Inc., Janssen Oncology Inc., and Janssen Research & Development LLC Under Fed. R. App. P. 8(a) for an Injunction Pending Appeal] (corresponding to Doc No. [12]) for Appellants BTG International Limited, Janssen Biotech, Inc., Janssen Oncology, Inc. and Janssen Research & Development, LLC. Service: 11/01/2018 by email. [562065] [19-1147] --[Edited 11/02/2018 by CAB to revise docket text] [Constantine Trela] [Entered: 11/01/2018 05:36 PM] (0) |
| Nov 1, 2018 | 14 | MOTION of Appellants BTG International Limited, Janssen Biotech, Inc., Janssen Oncology, Inc. and Janssen Research & Development, LLC to expedite. [Consent: not addressed]. Service: 11/01/2018 by email. [562066] [19-1147]--[Edited 11/02/2018 by CAB to revise docket text] [Constantine Trela] [Entered: 11/01/2018 05:39 PM] (16) |
| Nov 1, 2018 | 15 | MOTION of Appellants BTG International Limited, Janssen Biotech, Inc., Janssen Oncology, Inc. and Janssen Research & Development, LLC to seal document confidential document [13] [Consent: not addressed]. Service: 11/01/2018 by email. [562069] [19-1147] --[Edited 11/02/2018 by CAB to revise docket text] [Constantine Trela] [Entered: 11/01/2018 05:43 PM] (44) |
